Latest Research And Development News

ReNerve Limited has achieved its first commercial sales of the EmpliQ™ amniotic tissue products, marking a significant step in its transition from R&D to commercialisation. The EmpliQ™ range complements its existing nerve repair solutions and targets a growing global wound care market.

ClearVue Technologies has raised A$4.6 million in a strongly supported placement to accelerate international certification and ongoing innovation of its solar façade products.

Orthocell Limited has reported a record $3 million quarterly revenue, driven by strong sales of its nerve repair product Remplir in Australia and Singapore, while advancing its rollout in the US and Canada ahead of schedule.

Assetora Limited has released its audited FY25 financial report showing a significant reduction in losses and a strengthened capital position, highlighted by the reopening of the DomaCom Fund and a $3 million private placement. The company aims to leverage these developments to accelerate growth in funds under management.

DroneShield is investing $13 million over three years to open a new counter-drone research facility in Adelaide, marking a key step in its global growth and technology development.

Stakk Limited has successfully raised $15 million through an oversubscribed equity placement, underscoring strong institutional confidence in its Embedded Finance growth strategy. The funds will accelerate expansion in the U.S. and Australian markets as the company’s recurring revenue surges.

LTR Pharma has increased its ownership in LevOmega to approximately 43% through a strategic A$1 million investment, reinforcing its commitment to sustainable, pharmaceutical-grade omega-3 development.

Opthea Limited has received a substantial A$10.8 million R&D tax incentive from the Australian government, reinforcing its commitment to advancing its novel drug candidate sozinibercept. This funding milestone underscores the company’s strategic focus on innovation and fiscal discipline.

4DMedical has secured $22.6 million through the exercise of deep in-the-money options, significantly strengthening its cash position to support the commercial rollout of its CT – VQ™ respiratory imaging technology.

Invex Therapeutics has ended negotiations on two neurological asset acquisitions following due diligence setbacks and shareholder disputes, while advancing R&D collaborations and managing financial stability.

Memphasys Limited has announced a pro-rata entitlement offer to raise approximately $1.12 million, issuing new shares at $0.003 each with free attaching options, aiming to fund the commercialisation of its Felix™ system and strengthen working capital.

Quantum Graphite Ltd reported a significant revenue jump alongside a $4.9 million net loss for FY2025, as it pushes forward with its Uley 2 graphite project backed by major infrastructure and funding initiatives.